Chapter 22. Molecular Genetics of Cardiovascular Disorders

  1. Salim Yusuf DPhil, FRCPC, FRSC Research Chair Professor of Medicine Director Vice President Research3,4,5,
  2. John A Cairns MD, FRCPC Professor of Medicine Former Dean6,
  3. A John Camm MD British Heart Foundation Professor Head of Cardiac7,
  4. Ernest L Fallen MD, FRCPC Professor Emeritus8 and
  5. Bernard J Gersh MB, ChB, DPhil Consultant Professor of Medicine9
  1. Ali J Marian MD Professor of Molecular Medicine Internal Medicine (Cardiology) Director1 and
  2. Robert Roberts MD, FRCPC, MACC President CEO Professor of Medicine Director2

Published Online: 21 MAY 2010

DOI: 10.1002/9781444309768.ch22

Evidence-Based Cardiology, Third Edition

Evidence-Based Cardiology, Third Edition

How to Cite

Marian, A. J. and Roberts, R. (2009) Molecular Genetics of Cardiovascular Disorders, in Evidence-Based Cardiology, Third Edition (eds S. Yusuf, J. A. Cairns, A. J. Camm, E. L. Fallen and B. J. Gersh), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444309768.ch22

Editor Information

  1. 3

    McMaster University, Canada

  2. 4

    Population Health Research Institute, McMaster University, Hamilton Health Sciences, Canada

  3. 5

    Hamilton Health Sciences, Hamilton, Ontario, Canada

  4. 6

    Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

  5. 7

    St George's University of London, London, UK

  6. 8

    McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada

  7. 9

    Mayo Clinic College of Medicine, Rochester, MN, USA

Author Information

  1. 1

    Center for Cardiovascular Genetics, Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX, USA

  2. 2

    Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Publication History

  1. Published Online: 21 MAY 2010
  2. Published Print: 13 NOV 2009

ISBN Information

Print ISBN: 9781405159258

Online ISBN: 9781444309768



  • CV disease prevention;
  • CV risk factors;
  • fetal programming;
  • maternal health;
  • atherosclerosis


While it takes years for the morphological changes of atherosclerosis to develop and become manifest as clinical cardiovascular (CV) disease in middle age (1,2), origins of the disease may track from fetal life. Epidemiological evidence and animal studies implicate exposures in fetal life as determinants of obesity, Type 2 diabetes, and other CV risk factors that stimulate atherogenic processes leading to CV disease. Maternal health and nutrition during pregnancy and fetal growth and well-being may influence metabolic programming in the fetus, setting a trajectory culminating in the development of CV risk factors and ultimately CV disease. For prevention of CV disease future research must define the prevention strategies that can be implemented early in life and continue throughout the life-course.